Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 11Carcinoma, Renal Cell 8Lymphoma 7Neoplasm Metastasis 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Hematologic Neoplasms 5Glioblastoma 5Anus Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3HIV Infections 3Gliosarcoma 3Esophageal Neoplasms 3

Interventions

Temozolomide 4Bevacizumab 3Vorinostat 2Immunoglobulin G 2Disulfides 2veliparib 1romidepsin 1ispinesib 1cediranib 1Vincristine 1Prednisone 1Nivolumab 1Methotrexate 1Lomustine 1Lapatinib 1Irinotecan 1Ifosfamide 1Gelclair 1Fluorodeoxyglucose F18 1Etoposide 1Dexamethasone 1Clinical Laboratory Techniques 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CK0238273 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Spinal Cord Neoplasms × Nivolumab × Clear all
NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
133 enrolled
CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡